Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.60 |
| ▸ | TUBB | P07437 | 1/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.60 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.60 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.60 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265340 | 1.00 | MAPT (0.74) | MAPTMEN1KMT2ALMNAATM | |
| SCHEMBL4257060 | 0.88 | PTPN1 (0.75) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL4257063 | 0.88 | PTPN1 (0.75) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL4257415 | 0.86 | PTPN1 (0.63) | MAPTMEN1KMT2ALMNAATM | |
| SCHEMBL4257418 | 0.86 | PTPN1 (0.63) | MAPTMEN1KMT2ALMNAATM | |
| SCHEMBL4254456 | 0.85 | ABCG2 (0.67) | MAPTMEN1KMT2AABCG2NFE2L2 | |
| SCHEMBL4254451 | 0.85 | ABCG2 (0.67) | MAPTMEN1KMT2AABCG2NFE2L2 | |
| SCHEMBL4262025 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2ALMNAATM | |
| SCHEMBL4262031 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2ALMNAATM | |
| SCHEMBL5379059 | 0.84 | PTPN1 (0.73) | MAPTMEN1KMT2ALMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAPT 2548/4885MEN1 3991/4885KMT2A 4665/4885 |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAPT 2548/4885MEN1 3991/4885KMT2A 4665/4885 |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAPT 2548/4885MEN1 3991/4885KMT2A 4665/4885 |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAPT 2548/4885MEN1 3991/4885KMT2A 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.